Navigation Links
Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
Date:3/27/2008

h, cell differentiation and cell survival. KRX-0401, which is currently in Phase 2 clinical development for multiple tumor types, is expected to move into a Phase 3 clinical program in 2008. The Company also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

Cautionary Statement

As the Company has indicated in its public filings, among other things, clinical trials have a high risk of failure. A number of companies in the pharmaceutical industry, including biotechnology companies, have suffered significant setbacks in advanced clinical trials, even after achieving what appeared to be promising results in earlier trials.

Furthermore, as indicated in previous filings, interim results of preclinical or clinical studies do not necessarily predict their final results, and acceptable results in early studies might not be obtained in later studies. Drug candidates in the later stages of clinical development may fail to show the desired safety and efficacy traits despite positive results in initial clinical testing.

Additionally, as indicated in previous filings, there can be no assurance that the results from the Sulonex Phase 3 and/or Phase 4 study will track the data from the pilot Collaborative Study Group Phase 2 study or the DiNAS Phase 2 study. Results from these earlier Sulonex studies may not be indicative of results from future clinical trials.

Some of the statements included in this press release anticipating future clinical and business prospects may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: our ability to successfully adjust our strategy
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
2. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
5. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
6. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
7. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
8. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
11. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... IRVINE, Calif. , Oct 22, 2014 ... Irvine, California , announced the receipt ... Small Business Innovation Research award (SBIR) from the National Institute of ... will fund the development of a Pan-HIV Protein Microarray ... the HIV-1 and HIV-2 subtypes and aid in the ...
(Date:10/22/2014)... , Oct. 22, 2014 Moms are ... health trackers for themselves and their kids, according to ... Report: Health & Fitness Go Mobile for Moms, the ... Series. BabyCenter, the number 1 pregnancy and parenting web ... that 55 percent of moms surveyed say they can,t ...
(Date:10/22/2014)... PORTLAND, Oregon , October 22, 2014 ... titled, "Global Disposable Gloves Market (Product type, Form, End ... Company Profiles, Demand, Insights, Analysis, Research, Report, Opportunities, Segmentation ... the global disposable gloves market. Based on key trends ... to be valued at $7.9 billion by 2020, registering ...
Breaking Medicine Technology:Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4
(Date:10/25/2014)... New York, NY (PRWEB) October 26, 2014 ... aesthetic treatments, announces the most advanced and improved laser ... their effective and safe treatments like the lip ... treatments in keeping with specific focus areas of each ... services like cellulite reduction NYC . The company ...
(Date:10/25/2014)... Background: , In 1998 Bob Savage ... a pioneer in the field of establishing recovery community organizations. ... system and when he retired, he set out to answer ... service. , 1. Where are the people ... , 2. Can the recovery community be organized to ...
(Date:10/25/2014)... (PRWEB) October 25, 2014 Homeowners that ... has ‘gone bad’ need wonder no more. Clean Crawls ... homeowners should watch out for when it comes to ... according to the article released by Clean Crawls, can ... homeowners that any insulation that has deteriorated, become damp, ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, ... sores -- herpes simplex -- might increase the risk of ... fact, being a carrier of certain antibodies to the virus ... "The identification of a treatable cause [herpes simplex] ... lead researcher Dr. Hugo Lovheim, an associate professor in the ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, ... that spot increased risks for certain cancers, one might think ... But a new study suggests that, at least with ... out their genes doubled their risk of colon cancer were ... screened. "It didn,t make any difference, not at all," ...
Breaking Medicine News(10 mins):Health News:BioSkinLaser.Com Now Offers Advanced Medical Aesthetics Procedures 2Health News:BioSkinLaser.Com Now Offers Advanced Medical Aesthetics Procedures 3Health News:CCAR Accepting Nominations for the Bob Savage Recovery Advocate of the Year Award 2Health News:5 Signs Indicating That Insulation Needs Replacing as Told By Clean Crawls in Recent Article 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2
... of Thailand government. The country’s health minister Mongkol Na Songkhla ... rest of the nation. ,In a conference promoting ... rise at an alarming rate which leads to diabetes and ... said to suffer from diabetes. ,According to him ...
... that the same genetic regulator that triggers growth of ... role in the development of the lethal brain cancer ... they showed that knocking out the function of a ... ,The researchers said their findings suggest that targeting ...
... rights to commercial companies over clinical and preclinical trial ... medicines and harm public health, says Karin Timmermans of ... PLoS Medicine. ,Writing in a personal capacity, ... to produce generic versions of the "flu drug" oseltamivir ...
... a prominent hospital in Toronto for people with chronic diseases ... the Norwalk virus.// ,Diane Whidden, a spokesperson for ... affected. ,The hospital usually has hundreds of patients, ... are 20 active cases only in a capacity of 500-beds. ...
... mathematical model of disease cycles developed at the University ... ,Speaking in a symposium titled "New Vistas in ... meeting of the American Association for the Advancement of ... discuss how models that she and coworkers have developed ...
... dominated, the retro Sadhana cut and Dev Anand cowlick made ... gurus. ,Hair salons registered up to 75 percent ... spruced up on grooming rituals in preparation for Valentine's Day. ... went for a special hairdo - a crazy and more ...
Cached Medicine News:Health News:'Gateway' Gene Discovered for Brain Cancer 2Health News:Drug Companies Should Not Have a Monopoly Over Clinical Trial Data 2Health News:Mathematical Model Predicts Cholera Outbreaks 2Health News:Red Ribbons, Curls and Retro Hairstyles Popular on Valentine's Day 2
Latex agglutination slide test for the qualitative and semi-quantitative in vitro determination of Rheumatoid Factor in serum....
For the quantitative in vitro determination of Carbon Dioxide in serum and plasma....
For the quantitative in vitro determination of Uric Acid in serum, plasma and urine...
The BUN method used on the Dimension clinical chemistry system is an in vitro diagnostic test intended for the quantitative determination of urea nitrogen in serum, plasma and urine....
Medicine Products: